$VNDA -On May 19, 2022, Vanda Pharmaceuticals agreed to settle a securities fraud class action complaint (the “Complaint”) for $11.5 Million. https://grabarlaw.com/the-latest/vanda-pharmaceuticals-investigation/
VNDA 12.34 - FDA Approves HETLIOZ® (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome
Everything would be a lot better if the govt. would just let doctors treat COVID like another flu bug. The drama is getting old.
Yo, this thing is going to trade sideways for a while. They have a drug that could help with covid but so does every other pharma company. Its a safe hold imo but nothing will happen fast i don't think
What's up? Doesn't seem to be much interest. I was looking at the chart but haven't found much on the company yet.
LOL. VNDA GOT NEWS TODAY. SO WHAT DD HAVE YOU GOT TO SHARE?
Brett Jensen. SA article re VNDA. Expects positive analyst's review.
Vanda Pharmaceuticals (NASDAQ:VNDA) posted solid third quarter results on Thursday. Instead of losing a dime a share as expected, the company posted a profit of 11 cents a share. Revenue was also up more than 35% from the same period a year ago. The company now looks like it could be profitable in FY2017. I expect some positive analyst commentary on this name by analysts over the next week. Vanda has a solid pipeline and over $140 million in cash and marketable securities on the balance sheet. One has to like the company's growth trajectory and the concern seems undervalued with just a $600 million market capitalization.
Nice been following this stock for awhile now and made some good money here.
Also, follow Titan Pharmaceuticals TTNP
Vanda-Pharmaceuticals Reports Fourth-Quarter 2014 and Full-Year 2014 Financial-Results
Everything comes when you least expect!!!Patience!
Surprising not much interest in this stock it trades all over the place in the last year.
Not many investors. VNDA, have a very high margin requirement(70%)
Now I understand the new analyst target $ 6
These are the funds that bought in March 2014
FMR 4.52M $73.37M March 31, 2014
Baker Bros. Advisors 4.45M $72.24M March 31, 2014
Palo Alto Investors 3.22M $52.25M March 31, 2014
Kingdon Capital Management 1.91M $31.08M March 31, 2014
T. Rowe Price Associates 1.75M $28.47M March 31, 2014
STATE STREET CORPORATION 1.55M $25.26M March 31, 2014
GOLDMAN SACHS 1.53M $24.91M March 31, 2014
Inves 1.48M $24.12M March 31, 2014
Paulson & Co 1.39M $22.63M March 31, 2014
SUSQUEHANNA INTERNATIONAL 1.35M $21.92M March 31, 2014
BlackRock Fund Advisors 1.34M $21.71M March 31, 2014
Consonance Capital 1.23M $19.94M March 31, 2014
BVF 1.14M $4.45M March 31, 2013
BlackRock Institutional Trust Company, N.A. 1.08M $17.55M March 31, 2014
Vanguard 1.00M $16.30M March 31, 2014
WALL STREET ASSOCIATES 705100 $11.46M March 31, 2014
BOGLE INVESTMENT MANAGEMENT L P /DE/ 606489 $9.86M March 31, 2014
A total of 22.41 million shares more ( DILUTION)
Average Purchase $ 331,910,000
Average total purchase: $14.81
Now you understand, why they want that you buy?
Besides dilution want to steal. Less
Now I understand analysts TDA
S&P Capital IQ:No rating
Ford Equity Research: Strong Sell
Now one understands these ratings!
AMERICAN BULLS: MONDEY, CONFIRMATION: SELL!!
Our system’s recommendation today is to SELL. The BEARISH ONE BLACK CROW pattern finally received a confirmation because the prices crossed the confirmation level which was at 14,5800, and our valid average selling price stands now at 14,5000. The previous BUY recommendation was issued on 22/05/2014, 22 days ago, when the stock price was 9,9600. Since then VNDA has risen by +45,58%.
We may be at a market top or at the start of a correction. The market ran out of steam and the traders are now more in agreement about the bearishness. The evidence is strong enough to prompt the closing of long positions. Today’s candlestick has a black body and its close is below the confirmation level. The bearish pattern that was previously identified is finally confirmed and a SELL signal is generated. You still have time to follow the signal and then you may start checking other securities for a bullish bet. Less
ZACKS:Ariad Pharmaceuticals had the Lowest Relative Performance in the Biotechnology Industry (ARIA, MNKD, BCRX, INSM, VNDA)
Jun 13, 2014 (Fast Lane via COMTEX) -- Below are five companies in the Biotechnology industry that underperformed yesterday on a relative basis. This analysis was compiled based on yesterday's trading activity as we search for stocks that have could possible underperform its peers going forward.
Ariad Pharmaceuticals (NASDAQ:ARIA) ranks first with a loss of 8.69%; MannKind (NASDAQ:MNKD) ranks second with a loss of 5.51%; and BioCryst Pharmaceuticals (NASDAQ:BCRX) ranks third with a loss of 3.07%.
Insmed (NASDAQ:INSM) follows with a loss of 2.79% and Vanda Pharmaceuticals (NASDAQ:VNDA) rounds out the bottom five with a loss of 2.54%.ARIAD Pharmaceuticals, Inc. discovers and develops breakthrough medicines that regulate cell signaling with small molecules. The Company is primarily focused on product candidates for targeted indications. ARIAD is developing products to treat solid tumors, to block the spread of cancer, to treat certain forms of leukemia, and to treat cancer that has spread to bone and primary bone cancers. Less
F.TIME:Markit short selling activity is High! 06/13/14
News of China and USA, Irak, are not encouraging.
I think we will have a black friday
Whooooo! Now that's how winners play! Well done!
Sold half call position for 80%....so far total on Strangle trade 115%
Time to start coming back down, approval already baked into the stock price. This has been good company to me in the past. :)
Not sure what news could come out to help stock higher, the drug they just had approved as a very small patient population it will service.
I'm holding a small portion of calls through March.
They will push this down as far as they can. I'm sure many bought above $13 and $14 and are now stuck holding the bag. But this would be a good entry point for when more news does pop like you say.
Wait and see....patience. The CC could mention something that would be good for another 10% pop. Tea leaves about pricing of product or any number of factors could drive this one either direction pretty quickly.
Be ready and nimble....the pop (if at all) would likely be short lived. Seems conformation bias plagues this one.
News already priced in it seems. I've seen this a few times where a stock drops on news as opposed to sky rocketing. I think it will pull back a bit more as people jump ship.
Which is the exact reason I chose March options on this one. Let it shake out
Everyone looking to jump ship it seems....